Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Cyclo Therapeutics

June 21, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient

Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C

Continue reading

March 26, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics announces positive safety profile of its drug Trappsol Cyclo

Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

February 6, 2020 CD as API / CD derivatives / Pharma applications / Uncategorized

Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease

Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

October 25, 2019 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced

Continue reading

Posts pagination

«Previous Posts 1 2

Recent Posts

  • Call for Chapters: Cyclodextrins for Next-Generation Electronics and Energy Storage
  • Call for Chapters: Cyclodextrins in Nutraceuticals 
  • Comparison of the siRNA and mRNA Carrying Capacity of Quaternary Ammonium β-Cyclodextrin Polymer and Polyethylenimine
  • Call for Chapters: Cyclodextrins in Phytomedicine
  • Poly-CD-PEG-camptothecin Combined with Olaparib  in People With Relapsed/​Refractory Small Cell Lung Cancer (Clinical trial)

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (71)
  • CD as API (348)
  • CD derivatives (417)
  • Cosmetics and toilettry (52)
  • Diagnosis (13)
  • Drug delivery (798)
  • E-ducation (63)
  • Environmental (138)
  • Events (234)
  • Food (225)
  • Gene delivery (22)
  • Household products (5)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (43)
  • Non-pharma applications (403)
  • Other industrial use (109)
  • Pharma applications (1,191)
  • Supramolecular systems (42)
  • Uncategorized (153)

Top Posts

  • Cyclodextrin-based polymer materials and their applications - A review covering a 20-year period
  • Comparison of the siRNA and mRNA Carrying Capacity of Quaternary Ammonium β-Cyclodextrin Polymer and Polyethylenimine
  • Call for Chapters: Cyclodextrins in Nutraceuticals 
  • Lanosterol eye drops for cataract treatment
  • A review on sodium sulfobutylether-β-cyclodextrin (SBECD)
  • Special issue: Recent Trends in Carbohydrate-Based Therapeutics
  • Chloroquine against Covid-19?
  • 8th International Conference on Nanomaterials and Nanotechnology
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,474 other subscribers

Loading Comments...